Stryker and CMR Surgical have formed a strategic alliance to advance robotic-assisted surgery, with Stryker making an approximately $400 million investment in CMR Surgical. This collaboration will leverage CMR’s Versius surgical robotics portfolio and expertise alongside Stryker's extensive customer relationships and commercial reach. The agreement includes Stryker serving as the exclusive U.S. sales agent for the Versius products, while CMR continues to lead global development outside of the United States.
Written locally by qwen2.5:14b on 2026-10-12,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Strategic alliance combines CMR Surgical’s established platform and robotics expertise with Stryker’s scale, customer relationships and commercial reach to accelerate growth of the Versius Surgical Robotic portfolio
-
asserted
alliance → combine → portfolio
Stryker will make an approximately $400 million (£300 million) preferred equity investment in CMR Surgical to support future innovation and global commercialization of the Versius portfolio, subject to customary closing conditions
- The preferred equity investment also grants Stryker an exclusive option to acquire 100% of CMR Surgical’s outstanding equity in the future, subject to the agreement’s terms
- Stryker will serve as the exclusive U.S. sales agent for the Versius portfolio
Stryker (NYSE:SYK), a global leader in medical technologies, and CMR Surgical, a global robotics company, today announced a strategic equity investment of approximately $400 million (£300 million) by Stryker with an exclusive option for Stryker to acquire the remaining equity of CMR Surgical, and an exclusive U.S. commercial agency agreement for the Versius portfolio.
The agreement brings together CMR Surgical’s globally established soft-tissue robotics portfolio, clinical experience and culture of innovation with Stryker’s scale, deep customer relationships, commercial execution and proven track record of bringing innovative technologies to market.
asserted
agreement → make → market
Stryker will serve as the exclusive U.S. sales agent for the Versius portfolio, while CMR Surgical will continue to lead portfolio development and commercialization in markets outside the United States.
asserted
Surgical → serve → States
The alliance comes as demand for robotic-assisted surgery continues to grow, creating an opportunity to help healthcare providers expand robotic-assisted surgery programs with a scalable and practical solution.
asserted
providers → come → solution
CMR Surgical’s second-generation robot, with established clinical experience globally, supports a broad range of soft tissue procedures.
asserted
robot → establish → procedures
Designed for real-world operating environments, the Versius platform’s modular architecture supports flexibility across procedures, surgeon access and sites of care, and can help healthcare providers grow robotic adoption within existing operating room workflows.
asserted
providers → design → workflows
This scalable approach can help health systems meet growing demand for robotic-assisted surgery while preserving operational flexibility and supporting long-term program economics.
asserted
systems → help → economics
“Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker’s strengths in endoscopy, visualization and enabling technologies.
asserted
robotics → enable → endoscopy
We have evaluated the segment carefully for years, and this alliance represents a thoughtful and disciplined entry that combines the complementary strengths of both companies,” said Andy Pierce, Group President, Medsurg and Neurotechnology, Stryker.
asserted
Pierce → evaluate → companies
“We selected CMR Surgical and the Versius portfolio because of the opportunity to help healthcare providers grow robotic-assisted surgery adoption across a broad range of procedures in hospitals and ASCs.
asserted
providers → select → hospitals
“This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology, clinical experience and global business we have built,” said Massimiliano Colella, Chief Executive Officer of CMR Surgical.
asserted
Colella → build → Surgical
“Stryker’s investment will give us additional strength to accelerate innovation and the continued global expansion of the Versius portfolio, while its scale and deep customer relationships create a significant growth opportunity in the United States.
asserted
scale → give → States
We also look forward to welcoming Andy Pierce to our board of directors and benefiting from his more than 30 years of MedTech leadership experience at Stryker as we continue expanding access to robotic-assisted surgery globally.
asserted
We → look → surgery
Stryker’s exclusive acquisition option provides Stryker the opportunity to acquire 100% of CMR Surgical’s outstanding equity in the future, subject to the agreement’s terms.
asserted
option → provide → terms
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better.
asserted
healthcare → drive → customers
We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes.
asserted
that → offer → outcomes
Alongside our customers around the world, we impact more than 150 million patients annually.
asserted
we → impact → patients
CMR Surgical is a global medical devices company dedicated to transforming surgery with Versius Plus, a next-generation surgical robot.
asserted
Surgical → dedicate → Plus
Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable.
asserted
surgery → headquarter → tool
With Versius Plus, CMR Surgical is on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.
asserted
that → redefine → care
Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.
asserted
Surgical → found → base
The Aporia
